p16 as a biomarker to distinguish atypical ductal hyperplasia from ductal carcinoma in situ and to predict breast cancer progression

Authors

Judy A. Tjoe, Advocate Aurora HealthFollow
Brittany S. Last, Advocate Aurora HealthFollow
Jun Yin, Advocate Aurora HealthFollow

Recommended Citation

Tjoe J, Last B, Yin J. p16 as a biomarker to distinguish atypical ductal hyperplasia from ductal carcinoma in situ and to predict breast cancer progression. Ann Surg Oncol 2019;26(2 Suppl):53. doi: 10.1245/s10434-019-07407-7.

Affiliations

Advocate Aurora Health

Aurora Research Institute

Document Type

Abstract